Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

4.81
-0.0700-1.43%
Post-market: 4.810.00000.00%19:58 EDT
Volume:1.33M
Turnover:6.42M
Market Cap:352.31M
PE:-6.67
High:4.96
Open:4.89
Low:4.76
Close:4.88
52wk High:7.25
52wk Low:4.25
Shares:73.24M
Float Shares:45.48M
Volume Ratio:1.16
T/O Rate:2.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.7210
ROE:-64.58%
ROA:-25.95%
PB:6.79
PE(LYR):-6.67

Loading ...

Candel Therapeutics Director Paul B. Manning Acquires Common Shares

Reuters
·
Feb 27

Candel Therapeutics CEO Paul Peter Tak to Present at TD Cowen’s 46th Annual Health Care Conference

Reuters
·
Feb 24

Candel Therapeutics Announces Equity Offering to Fund CAN-2409

TIPRANKS
·
Feb 23

BRIEF-Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock

Reuters
·
Feb 21

Candel Therapeutics Inc - Files for Offering of 18.3 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Feb 21

BUZZ-U.S. STOCKS ON THE MOVE-Homebuilders, solar stocks, Alphabet

Reuters
·
Feb 21

BUZZ-U.S. STOCKS ON THE MOVE-Deckers Outdoor, CDT Equity, Comfort Systems

Reuters
·
Feb 20

BUZZ-U.S. STOCKS ON THE MOVE-Akamai, Grail, Candel Therapeutics

Reuters
·
Feb 20

Shares of Candel Therapeutics Down 12.8% Premarket After Pricing $100 Mln Equity Offering

THOMSON REUTERS
·
Feb 20

Why Is Candel Therapeutics Stock Falling Friday?

Benzinga_recent_news
·
Feb 20

Candel Therapeutics Announces Pricing Of Public Offering Of 18,348,624 Shares At $5.45 Each

Reuters
·
Feb 20

Candel Therapeutics Inc - Prices Public Offering of 18,348,624 Shares at $5.45 Each

THOMSON REUTERS
·
Feb 20

Candel Therapeutics Secures $100M Royalty Funding for CAN-2409

TIPRANKS
·
Feb 20

BRIEF-Candel Therapeutics Announces Proposed $100 Million Public Offering

Reuters
·
Feb 20

BUZZ-Candel Therapeutics falls after announcing $100 mln stock offering, royalty agreement

Reuters
·
Feb 20

Candel Therapeutics announces $100M common stock offering

TIPRANKS
·
Feb 20

Candel Therapeutics Inc - Proceeds to Fund Aglatimagene Launch and Phase 3 Trial Costs

THOMSON REUTERS
·
Feb 20

Candel Therapeutics Secures $100M Royalty Funding Agreement With RTW Investments

Reuters
·
Feb 20

Candel Therapeutics: Under Agreement, Rtw Will Receive a Tiered Single Digit Percentage of Annual Net Sales of Aglatimagene in U.S. Subject to a Cap

THOMSON REUTERS
·
Feb 20

Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit

Reuters
·
Feb 11